Fengling Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fengling Wang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Wei Wang
Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, China
14 shared publications - Haozhan Gao
Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, China
13 shared publications - Yalan Zhang
Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, China
13 shared publications - Yong Huang
Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
13 shared publications - Feiyang Yan
Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
12 shared publications - Jing Li
Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
12 shared publications
Latest Publications
- 2 April 2026
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 33 (6) , 718-729
Zoledronic acid enhances the antitumor efficacy of the PSMA CAR-T cells for bone tumors, but impedes the ability to control metastases of prostate cancer in mice
The chimeric antigen receptor (CAR)-T cell therapy has shown promise for the treatment of hematological and solid tumors. Although CAR-T cells targeting PSMA showed robust antitumor efficacy for prostate cancer in preclinical studies, the clinical benefits of PSMA CAR-T cells are unsatisfactory. To maximize the efficacy of this immunotherapy, we combined zoledronic acid (ZOL), a first-line prophylactic drug against skeletal-related events (SREs) and for bone pain management in patients with advanced prostate cancer, with PSMA CAR-T cells for the treatment of prostate cancer. In mice with intratibial inoculation of 22Rv1 prostate tumor, ZOL treatment after PSMA CAR-T cells infusion inhibited growth of the primary intratibial tumor, while it increased the extraskeletal metastasis, demonstrating that ZOL impedes the long-term immunosurveillance, albeit it enhances the short-term antitumor capability of the CAR-T cells. Mechanistically, ZOL showed no increase in the frequency of γδT cell phenotype. Finally, we found that ZOL induced hyperactivation and eventually led to exhaustion of the PSMA CAR-T cells, elucidating the impediment clues of ZOL on the T cell therapy. Our study demonstrates the necessity to balance the contribution of ZOL when combined with CAR-T cell therapy for prostate cancer.
- 2 April 2026
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 33 (6) , 718-729
Zoledronic acid enhances the antitumor efficacy of the PSMA CAR-T cells for bone tumors, but impedes the ability to control metastases of prostate cancer in mice
The chimeric antigen receptor (CAR)-T cell therapy has shown promise for the treatment of hematological and solid tumors. Although CAR-T cells targeting PSMA showed robust antitumor efficacy for prostate cancer in preclinical studies, the clinical benefits of PSMA CAR-T cells are unsatisfactory. To maximize the efficacy of this immunotherapy, we combined zoledronic acid (ZOL), a first-line prophylactic drug against skeletal-related events (SREs) and for bone pain management in patients with advanced prostate cancer, with PSMA CAR-T cells for the treatment of prostate cancer. In mice with intratibial inoculation of 22Rv1 prostate tumor, ZOL treatment after PSMA CAR-T cells infusion inhibited growth of the primary intratibial tumor, while it increased the extraskeletal metastasis, demonstrating that ZOL impedes the long-term immunosurveillance, albeit it enhances the short-term antitumor capability of the CAR-T cells. Mechanistically, ZOL showed no increase in the frequency of γδT cell phenotype. Finally, we found that ZOL induced hyperactivation and eventually led to exhaustion of the PSMA CAR-T cells, elucidating the impediment clues of ZOL on the T cell therapy. Our study demonstrates the necessity to balance the contribution of ZOL when combined with CAR-T cell therapy for prostate cancer.
- Open Access
- 12 February 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 196, 119110
Membrane-proximal binding of PSMA facilitates synapse formation with CAR and enhances antitumor activity of PSMA CAR-T cells against prostate cancer
- 12 February 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 196, 119110
Open AccessMembrane-proximal binding of PSMA facilitates synapse formation with CAR and enhances antitumor activity of PSMA CAR-T cells against prostate cancer
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses
Supplementary figure 2 shows the gating strategy for CAR-T differentiation and exhaustion.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses
Supplementary figure 2 shows the gating strategy for CAR-T differentiation and exhaustion.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses
Supplementary figure 9 shows the H&E staining of various tissues in BALB/c abdominal colon cancer animal model.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses
Supplementary figure 9 shows the H&E staining of various tissues in BALB/c abdominal colon cancer animal model.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses
Supplementary figure 5 shows the changes of immune cells in spleen and peripheral blood of mice after CD24 CAR-T infusion.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses
Supplementary figure 5 shows the changes of immune cells in spleen and peripheral blood of mice after CD24 CAR-T infusion.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Data from CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses
Chimeric antigen receptor–modified T (CAR-T) cell therapy has achieved remarkable progress in the treatment of B-cell malignancies, whereas suboptimal therapeutic outcomes have been observed in solid tumors. Immunosuppression from microenvironment of tumors causing decreased killing ability, poor expansion, and persistence of CAR-T cells results in reduced efficacy. Endeavors aimed at eliciting endogenous immune responses have been found to enhance and sustain the antitumor effects of CAR-T cell therapy. In this study, we reported that CAR-T cells targeting cluster of differentiation 24 (CD24), a potential tumor biomarker and an innate immune checkpoint molecule, evoked robust antitumor efficacy and elicited long-term tumor regression. CD24-targeted CAR-T (CD24 CAR-T) cells showed strong cytotoxicity to CD24-positive cancer cells in vitro and mediated inhibition of tumor growth in immunodeficient mice. Moreover, in immunocompetent mice, CD24 CAR-T cells exhibited robust antitumor ability without side effects. Of note, mice that received CD24 CAR-T cells withstood both CD24-positive and CD24-negative tumors rechallenge. We detected a high level of IFN-γ release in splenic lymphocytes of the rechallenged mice, as well as tumor-reactive antibody in serum, indicating the endogenous tumor immune responses was activated. In summary, our findings showed that CD24 CAR-T cells targeting immune checkpoint have superior antitumor efficacy in preclinical models and may provide a strategy for the treatment of solid tumors.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses
Chimeric antigen receptor–modified T (CAR-T) cell therapy has achieved remarkable progress in the treatment of B-cell malignancies, whereas suboptimal therapeutic outcomes have been observed in solid tumors. Immunosuppression from microenvironment of tumors causing decreased killing ability, poor expansion, and persistence of CAR-T cells results in reduced efficacy. Endeavors aimed at eliciting endogenous immune responses have been found to enhance and sustain the antitumor effects of CAR-T cell therapy. In this study, we reported that CAR-T cells targeting cluster of differentiation 24 (CD24), a potential tumor biomarker and an innate immune checkpoint molecule, evoked robust antitumor efficacy and elicited long-term tumor regression. CD24-targeted CAR-T (CD24 CAR-T) cells showed strong cytotoxicity to CD24-positive cancer cells in vitro and mediated inhibition of tumor growth in immunodeficient mice. Moreover, in immunocompetent mice, CD24 CAR-T cells exhibited robust antitumor ability without side effects. Of note, mice that received CD24 CAR-T cells withstood both CD24-positive and CD24-negative tumors rechallenge. We detected a high level of IFN-γ release in splenic lymphocytes of the rechallenged mice, as well as tumor-reactive antibody in serum, indicating the endogenous tumor immune responses was activated. In summary, our findings showed that CD24 CAR-T cells targeting immune checkpoint have superior antitumor efficacy in preclinical models and may provide a strategy for the treatment of solid tumors.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses
Supplementary figure 1 shows expression of CD24 on 293T and IOSE-80 cell lines.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses
Supplementary figure 1 shows expression of CD24 on 293T and IOSE-80 cell lines.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses
This table presented all sequence of each component of the human and murine CAR molecules used in the manuscript, as well as the complete sequence of CAR molecules.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses
This table presented all sequence of each component of the human and murine CAR molecules used in the manuscript, as well as the complete sequence of CAR molecules.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses
Supplementary figure 8 shows the body weight change of mice.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses
Supplementary figure 8 shows the body weight change of mice.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses
Supplementary figure 6 shows the flow cytometry gating strategy for mouse T cells, B cells, NK cells, and monocytes.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses
Supplementary figure 6 shows the flow cytometry gating strategy for mouse T cells, B cells, NK cells, and monocytes.